Publication:

Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient

Loading...
Thumbnail Image

Open/View Files

Date

2013

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

MDPI
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Abhyankar, Anita, Elliot Tapper, and Alan Bonder. 2013. “Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient.” Pharmaceuticals 7 (1): 18-28. doi:10.3390/ph7010018. http://dx.doi.org/10.3390/ph7010018.

Abstract

Autoimmune liver disease management goals are primarily slowing disease progression and symptomatic treatment. There are few options for curative medical management other than transplant for a spectrum of autoimmune liver disease that encompasses autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis as well as their overlap syndromes. These diseases are managed primarily with immunosuppressive therapy. Herein, we review the current literature, detailing the promise and pitfalls of the recommended immunosuppressive therapy for these challenging diseases.

Description

Research Data

Keywords

autoimmune liver disease, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, overlap syndrome

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories